Biogen Inc.

Company facts

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

Cambridge, Massachusetts

Most recent report

10-Q, filed Oct 28, 2026

Incorporated

Delaware

Filings on record

1,001+ filings

On EDGAR

CIK 875045

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 4 of 10 sections worth reading, with 0 positive, 19 notable, and 2 negative flags.

• Part I

  Apellis acquisition, net loss, cash burn, restructuring, and litigation details are all company-specific.
  Notable

  • Three wholesalers accounted for 30.3%, 16.9%, and 11.5% of gross product revenue in Q3 2026.
  • Genentech litigation: court entered judgment against Biogen for ~$124.3M in Nov 2025; appeal pending.
  • Germany tax matter: assessments of ~€209.8M including interest; Biogen is challenging.

• Management's Discussion (Item 2)

  Dense with acquisition impacts, revenue shifts, tariff exposure, and pipeline updates.
  Notable

  • U.S. imposed 100% tariff on patented pharma imports under Section 232, effective July/Sept 2026.
  • IRA Medicare Part D redesign had a modest net unfavorable impact on SKYCLARYS and MS portfolio revenue.
  • ZURZUVAE revenue up 52.6% to $84.4M in Q3 2026, driven by continued U.S. launch.
  • Apellis acquisition closed May 14, 2026 for $5.3B cash, funded by $2.0B term loan and $400M revolver draw.
  • RayThera acquisition in Aug 2026: $225M upfront plus up to $775M in milestones for a Phase 1 immunology asset.
  • BIIB122 Phase 2b LUMA study failed; development discontinued in idiopathic Parkinson's disease.
  • SPINRAZA high-dose regimen approved by FDA in March 2026; U.S. revenue up 60.8% in Q3 2026.
  • Restructuring charges of $66.5M in Q3 2026, primarily for Apellis integration severance and bonus acceleration.
  • No share repurchases in Q3 2026 or Q3 2025; $2.1B remains available under the 2020 program.
  • Potential future milestone payments to third parties up to $8.1B, including $5.7B in commercial milestones.

• Controls and Procedures (Item 4)

  Acquisition of Apellis on May 14, 2026, with ongoing integration of internal controls.
  Notable

  • Apellis acquisition closed May 14, 2026; integration of internal controls is ongoing.

• Risk Factors (Item 1A)

  Multiple recent, company-specific risks: 100% pharma tariff, Apellis acquisition, OBBBA law, LEQEMBI approval.
  Notable

  • FDA approved subcutaneous LEQEMBI (July 2026), but success depends on commercial launch and patient adoption.
  • Acquisition of Apellis (May 2026) adds integration risk for EMPAVELI and SYFOVRE. Success not assured.
  • OBBBA (July 2025) may materially change Medicaid funding; impact uncertain but Biogen says it could be material.
  • IRA drug pricing controls expected to hit sales of Medicare-reliant products, as stated in the filing.
  • Large-scale biologics facility in Solothurn, Switzerland, no assurance capacity will be used; risk of impairment charges.
  Negative

  • A single CRO handles most clinical trial activities; if it fails, many trials could be delayed or fail.
  • 100% tariff on patented pharma imports (April 2026) directly raises costs for Biogen's international supply chain.

What changed: Sep 2026 vs. Jun 2026

About 4% of BIIB's Sep 2026 10-Q is new information. 51 paragraphs were added, 319 changed, and 74 removed. Below are the most important lines SECSift identified.

• Item 2 171
• Part I 99
• Item 1A 25
• Item 3 4
• Item 5 2
• Item 4 2
• Item 6 2
• Item 1 1